BOLT
NASDAQBolt Biotherapeutics Inc.
Price$4.75+0.21 (+4.74%)
2026-03-042026-06-05
News · 26 weeks22-80%
2025-12-142026-06-07
Mix1090d
- SEC Filings7(70%)
- Other2(20%)
- Analyst1(10%)
Latest news
25 items- ANALYSTRodman & Renshaw initiated coverage on Bolt Biotherapeutics with a new price targetRodman & Renshaw initiated coverage of Bolt Biotherapeutics with a rating of Buy and set a new price target of $22.00
- SECSEC Form 10-Q filed by Bolt Biotherapeutics Inc.10-Q - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- SECBolt Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- PRBolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateFirst-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose escalation portion of the ongoing BDC-4182 Phase 1/2 study REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. "We are encouraged by what we have seen thus far in patients treated with BDC
- SECSEC Form DEFA14A filed by Bolt Biotherapeutics Inc.DEFA14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- SECSEC Form DEF 14A filed by Bolt Biotherapeutics Inc.DEF 14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- SECSEC Form S-8 filed by Bolt Biotherapeutics Inc.S-8 - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- SECSEC Form 10-K filed by Bolt Biotherapeutics Inc.10-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- SECBolt Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
- PRBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateFirst-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update. "BDC-4182 is the first of our next-generation Boltbody™ ISACs to enter the clinic, and we saw a clear difference versus our first-gen
- PRBolt Biotherapeutics to Participate in Upcoming March ConferencesREDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 46th Annual Health Care ConferenceCompany presentation on Monday, March 2, 2026 at 9:50 a.m. EST (6:50 a.m. PST)Leerink Partners Global Healthcare ConferenceParticipating in 1x1 meetings on Wednesday, March 11, 2026 About Bolt Biotherapeutics, Inc.The mission of Bolt Biotherapeutics is to harness the power of the immune system to improve lives and eradicate cancer. The Company is developing BDC-4182,
- INSIDERPresident, CEO and CFO Quinn William P. bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 6% to 2,313 units (SEC Form 4)4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Yonehiro Grant4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSenior VP, Finance and PAO Nemec Sarah bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 10% to 1,415 units (SEC Form 4)4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSEC Form 4 filed by Director Dupont Jakob4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSEC Form 4 filed by Director Onetto Nicole4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSEC Form 4 filed by Director Berner Laura4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSEC Form 4 filed by Director Laporte Kathleen4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSEC Form 4 filed by Director O'Callaghan Brian4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSEC Form 4 filed by Senior VP, Finance and PAO Nemec Sarah4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Yonehiro Grant4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO and CFO Quinn William P.4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bolt Biotherapeutics Inc.SCHEDULE 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bolt Biotherapeutics Inc.SCHEDULE 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)
- SECSEC Form 10-Q filed by Bolt Biotherapeutics Inc.10-Q - Bolt Biotherapeutics, Inc. (0001641281) (Filer)
BOLT FAQ
7 questionsWhat does Bolt Biotherapeutics Inc. do?
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators...Where does BOLT stock trade?
Bolt Biotherapeutics Inc. (BOLT) is listed on NASDAQ.What sector and industry is BOLT in?
Bolt Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Bolt Biotherapeutics Inc. go public?
Bolt Biotherapeutics Inc. (BOLT) completed its IPO in 2021.What are analysts saying about BOLT?
Bolt Biotherapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $2200.00 price target on 2026-05-29. Recent price targets range from $700.00 to $3500.00.What companies are similar to BOLT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BOLT side-by-side with any of them on Quantisnow.How can I track BOLT on Quantisnow?
Quantisnow aggregates Bolt Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BOLT to receive live email and push alerts on every new disclosure.